SCHEMBL4510753

SCHEMBL4510753

C#CCNC[C]=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38356 0.83
SCHEMBL2428440 0.83
Hydrochloric Acid SCHEMBL11469944 0.79
SCHEMBL11798220 0.69 SAT1 (0.57)
SCHEMBL23662996 0.69
SCHEMBL4516497 0.69
SCHEMBL137444 0.67
SCHEMBL2190850 0.67
SCHEMBL3376137 0.67
SCHEMBL4494356 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120231996-A1 Phalloidin derivatives and methods for their synthesis NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-09-13 US claimed
EP-1078002-B1 PEPTIDE ANTIANGIOGENIC DRUGS ABBOTT LAB (US) 2008-05-21 EP claimed
US-20050124548-A1 Peptide antiangiogenic drugs HENKIN JACK (US) 2005-06-09 US claimed
US-6777535-B1 USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS ABBOTT LABORATORIES 2004-08-17 US claimed
US-6753408-B1 DRUGS USED FOR THERAPY ABBVIE INC. 2004-06-22 US claimed
EP-1421107-A1 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY Abbott Laboratories (US) 2004-05-26 EP claimed
US-6716963-B1 OLIGOPEPTIDES ABBOTT LABORATORIES 2004-04-06 US claimed
US-20030050246-A1 Peptides having antiangiogenic activity ABBOTT LABORATORIES 2003-03-13 US claimed
US-20030045477-A1 Peptides having antiangiogenic activity ABBOTT LABORATORIES 2003-03-06 US claimed
WO-2003011896-A1 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2003-02-13 WO claimed
EP-1242455-A1 N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY Abbott Laboratories (US) 2002-09-25 EP claimed
EP-1232183-A2 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2002-08-21 EP claimed
WO-2001038347-A2 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2001-05-31 WO claimed
WO-2001038397-A1 N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2001-05-31 WO claimed
EP-1078002-A1 PEPTIDE ANTIANGIOGENIC DRUGS ABBOTT LABORATORIES (US) 2001-02-28 EP claimed
WO-1999061476-A1 PEPTIDE ANTIANGIOGENIC DRUGS ABBOTT LABORATORIES (US) 1999-12-02 WO claimed
CN-106459148-B Novel antimicrobial compounds, reaction media containing the same, and uses thereof 生物梅里埃公司 2020-11-13 CN disclosed
US-9969758-B2 Antimicrobial compounds BIOMERIEUX (FR) 2018-05-15 US disclosed
EP-0132441-A1 ANTIBACTERIAL PEPTIDES UNIVERSITY PATENTS, INC. (US) 1985-02-06 EP disclosed
WO-1984002905-A1 ANTIBACTERIAL PEPTIDES UNIVERSITY PATENTS INC (US) 1984-08-02 WO disclosed